Thursday, September 10, 2026
The Cancer News
AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Sasha Stanton, MD, PhD
a physician-scientist and assistant member
the Earle A. Chiles Research Institute, Providence Cancer Institute in Portland, Oregon
Published Articles (1)
Precision Over Protocol: What's New in HR-Positive, HER2-Negative Breast Cancer
July 17, 2026
Hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer is the most common subtype of breast cancer and its treatment landscape has never been more complex or more promising.